Loading…
Sectoral / Thematic · quant Mutual Fund · AMFI code 151853quant Healthcare Fund
Disclosed for 38 months, Aug 2023 to Sep 2026.
Portfolio value
₹352 Cr
up ₹25.3 Cr vs Mar 2026
- Stocks held
- 15
- unchanged
- Top 10 weight
- 75.1%
- of the portfolio in its ten largest
- Cash & debt
- 11.0%
- cash, money market and debt
quant Healthcare Fund is an active equity fund in the Sectoral / Thematic category from quant Mutual Fund. In April 2026 it disclosed 15 stocks worth ₹352 Cr, up ₹25.3 Cr from Mar 2026. Its largest positions were Zydus Wellness Limited (9.3%), Anthem Biosciences Limited (9.2%), Aster DM Healthcare Limited (8.9%); the ten largest together made up 75.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 56.7% of its equity. Cash and debt stood at 11.0%. Compared with Mar 2026 the fund entered 2 new stocks and exited 2.
Against 229 other Sectoral / Thematic funds
Concentration
96%
Top-10 weight is higher than 96% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
97%
Holds more cash than 97% of peers
What these mean: concentration · cash
Holdings in April 2026
Download CSVEvery line the fund disclosed, with the change against Mar 2026. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Zydus Wellness Limited | 9.27% | up 0.90 pts | ₹32.6 Cr | up ₹5.3 Cr | Added |
| Anthem Biosciences Limited | 9.17% | down 0.13 pts | ₹32.3 Cr | up ₹1.9 Cr | Added |
| Aster DM Healthcare Limited | 8.90% | down 0.26 pts | ₹31.3 Cr | up ₹1.4 Cr | Added |
| SMS Pharmaceuticals Limited | 8.86% | down 1.56 pts | ₹31.2 Cr | down ₹2.8 Cr | Trimmed |
| Sequent Scientific Limited | 8.62% | up 0.29 pts | ₹30.3 Cr | up ₹3.1 Cr | Added |
| Glenmark Life Sciences Limited | 7.27% | down 0.07 pts | ₹25.6 Cr | up ₹1.6 Cr | Added |
| HFCL Limited | 7.14% | up 7.14 pts | ₹25.1 Cr | up ₹25.1 Cr | New |
| Pfizer Limited | 6.42% | down 0.51 pts | ₹22.6 Cr | down ₹5 L | Held |
| Aurobindo Pharma Limited | 5.15% | down 0.06 pts | ₹18.1 Cr | up ₹1.1 Cr | Added |
| Cash, TREPS & receivables | 5.11% | up 11.74 pts | ₹18 Cr | up ₹39.7 Cr | Added |
| ICICI Prudential Life Insurance Company Limited | 4.35% | down 0.30 pts | ₹15.3 Cr | up ₹13 L | Added |
| HDFC Life Insurance Company Limited | 3.80% | down 0.32 pts | ₹13.4 Cr | down ₹8 L | Trimmed |
| MedPlus Health Services Limited | 3.72% | down 0.14 pts | ₹13.1 Cr | up ₹48 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 2.16% | down 0.11 pts | ₹7.6 Cr | up ₹17 L | Added |
| 91 Days Treasury Bill 22-May-2026 Debt | 1.70% | down 0.12 pts | ₹6 Cr | up ₹3 L | Held |
| Gland Pharma Limited | 1.40% | down 0.06 pts | ₹4.9 Cr | up ₹15 L | Added |
| ICICI Bank Limited 26/05/2026 Derivative | 1.34% | up 1.34 pts | ₹4.7 Cr | up ₹4.7 Cr | New |
| HDFC Life Insurance Co Ltd 26/05/2026 Derivative | 1.11% | up 1.11 pts | ₹3.9 Cr | up ₹3.9 Cr | New |
| 91 Days Treasury Bill 07-May-2026 Debt | 0.85% | down 0.06 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 14-May-2026 Debt | 0.85% | down 0.06 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 04-Jun-2026 Debt | 0.85% | down 0.06 pts | ₹3 Cr | up ₹1 L | Held |
| 91 Days Treasury Bill 16-Jul-2026 Debt | 0.84% | up 0.84 pts | ₹3 Cr | up ₹3 Cr | New |
| 91 Days Treasury Bill 23-Jul-2026 Debt | 0.84% | up 0.84 pts | ₹3 Cr | up ₹3 Cr | New |
| Strides Pharma Science Limited | 0.30% | up 0.30 pts | ₹1.1 Cr | up ₹1.1 Cr | New |
What changed, Mar 2026 to Apr 2026
New New positions (2)
- HFCL Limited7.1% · ₹25.1 Cr
- Strides Pharma Science Limited0.3% · ₹1.1 Cr
Exited Exited (2)
- Concord Biotech Limitedwas 2.6% · ₹8.5 Cr
- Adani Enterprises Limitedwas 0.6% · ₹2 Cr
Added Biggest additions
- Zydus Wellness Limitedup ₹5.3 Cr (+0.90% pts)
- Sequent Scientific Limitedup ₹3.1 Cr (+0.29% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Mar 2026, the weight rose most in Telecom - Services (+8.3 pts) and Food Products (+0.8 pts), and fell most in Pharmaceuticals & Biotechnology (−7.0 pts) and Insurance (−0.9 pts).
- Telecom - Services0.0% → 8.3%new+8.3 pts
- Food Products9.9% → 10.7%+0.8 pts
- Pharmaceuticals0.0% → 0.3%new+0.3 pts
- Pharmaceuticals & Biotechnology63.6% → 56.7%−7.0 pts
- Insurance10.4% → 9.4%−0.9 pts
- Metals & Minerals Trading0.7% → 0.0%exited−0.7 pts
- Healthcare Services10.8% → 10.3%−0.5 pts
- Retailing4.6% → 4.3%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Apr 2025 | Oct 2025 | Jan 2026 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 66.0% | 68.6% | 67.8% | 63.6% | 56.7% |
| Food Products | 6.7% | 10.1% | 11.0% | 9.9% | 10.7% |
| Healthcare Services | 13.6% | 10.0% | 9.4% | 10.8% | 10.3% |
| Insurance | — | — | — | 10.4% | 9.4% |
| Telecom - Services | 5.6% | — | — | — | 8.3% |
| Retailing | — | — | 4.6% | 4.6% | 4.3% |
| Pharmaceuticals | — | — | — | — | 0.3% |
Allocation in Apr 2026change vs Mar 2026
- Pharmaceuticals & Biotechnology (8)56.7%▼ 7.0 pts
- Food Products (1)10.7%▲ 0.8 pts
- Healthcare Services (1)10.3%▼ 0.5 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Apr 2026
11.0%
▲ 11.0 pts vs Mar 2026
- Cash alone
- 5.1%
- cash and net receivables
- A year earlier
- 0.9%
- Apr 2025 · now ▲ 10.1 pts
- Last 12 months
- 0.1% – 11.0%
- lowest to highest · record 11.0% in Apr 2026
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.